REGENXBIO Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
RGNX$7.69-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data)
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues | ||
| License and royalty revenue | $156,267 | $81,960 |
| Service revenue | 14,174 | 1,368 |
| Total revenues | 170,441 | 83,328 |
| Operating Expenses | ||
| Cost of license and royalty revenues | 20,298 | 33,567 |
| Research and development | 228,299 | 208,522 |
| General and administrative | 82,863 | 76,619 |
| Credit losses (recoveries) | — | (5,000) |
| Impairment of long-lived assets | — | 2,101 |
| Other operating expenses | 179 | 865 |
| Total operating expenses | 331,639 | 316,674 |
| Loss from operations | (161,198) | (233,346) |
| Other Income (Expense) | ||
| Interest income from licensing | 83 | 174 |
| Investment income | 12,245 | 18,729 |
| Interest expense | (45,008) | (12,659) |
| Total other income (expense) | (32,680) | 6,244 |
| Net loss | $(193,878) | $(227,102) |
| Other Comprehensive Income | ||
| Unrealized gain on available-for-sale securities, net | 54 | 3,688 |
| Total other comprehensive income | 54 | 3,688 |
| Comprehensive loss | $(193,824) | $(223,414) |
| Net loss per share, basic and diluted | $(3.76) | $(4.59) |
| Weighted-average common shares outstanding, basic and diluted | 51,573 | 49,509 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.